Authors
Loading...
Randomized double-blind trial demonstrates reduced 28-day mortality with Xuebijing injection in sepsis patients, indicating potential survival benefits.
Liu et al. (2023) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: